--- title: "Ethzilla (ETHZ.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/ETHZ.US.md" symbol: "ETHZ.US" name: "Ethzilla" industry: "Biotechnology" datetime: "2026-05-20T10:48:40.611Z" locales: - [en](https://longbridge.com/en/quote/ETHZ.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ETHZ.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ETHZ.US.md) --- # Ethzilla (ETHZ.US) ## Company Overview ETHZilla Corporation operates a technology company focused on Ethereum-based infrastructure for the tokenization of real-world assets. The company develops platforms that enable the conversion of illiquid, institutional-grade assets into blockchain-based financial instruments using Ethereum Layer 2 protocols. It bridges traditional finance and blockchain technology by supporting regulated access, scalability, and efficiency in asset tokenization. The company was formerly known as 180 Life Sciences Corp. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:13.000Z **Overall: D (0.70)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 342 / 386 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 0.00% | | | Net Profit YoY | -7367.61% | | | P/B Ratio | 0.00 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 0.00 | | | Revenue | 4110169.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -100.04% | E | | Profit Margin | -5476.94% | E | | Gross Margin | 100.00% | A | | Revenue YoY | 0.00% | D | | Net Profit YoY | -7367.61% | E | | Total Assets YoY | 9540.18% | A | | Net Assets YoY | 11821.92% | A | | Cash Flow Margin | 8.30% | D | | OCF YoY | 0.00% | C | | Turnover | 0.01 | E | | Gearing Ratio | 55.90% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Ethzilla", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "0.00%", "rating": "" }, { "name": "Net Profit YoY", "value": "-7367.61%", "rating": "" }, { "name": "P/B Ratio", "value": "0.00", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "0.00", "rating": "" }, { "name": "Revenue", "value": "4110169.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-100.04%", "rating": "E" }, { "name": "Profit Margin", "value": "-5476.94%", "rating": "E" }, { "name": "Gross Margin", "value": "100.00%", "rating": "A" }, { "name": "Revenue YoY", "value": "0.00%", "rating": "D" }, { "name": "Net Profit YoY", "value": "-7367.61%", "rating": "E" }, { "name": "Total Assets YoY", "value": "9540.18%", "rating": "A" }, { "name": "Net Assets YoY", "value": "11821.92%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "8.30%", "rating": "D" }, { "name": "OCF YoY", "value": "0.00%", "rating": "C" }, { "name": "Turnover", "value": "0.01", "rating": "E" }, { "name": "Gearing Ratio", "value": "55.90%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.29 | 114/386 | - | - | - | | PB | 0.15 | 7/386 | 61.62 | 0.22 | 0.15 | | PS (TTM) | 16.33 | 188/386 | 25.86 | 16.33 | 16.33 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2023-02-14T05:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 3.53 | | Highest Target | undefined | | Lowest Target | undefined | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ETHZ.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ETHZ.US/norm.md) - [Related News](https://longbridge.com/en/quote/ETHZ.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ETHZ.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**